Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lin BioScienceROCO:6696 -5.08%25 Buyback Yield % is -0.15 as of Jul. 30, 2026. GuruFocus rates ROCO:6696 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 735 Biotechnology companies, Lin BioScience ranks better than 80% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Lin BioScience's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6696 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Lin BioScience's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lin BioScience Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lin BioScience's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Lin BioScience's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lin BioScience (ROCO:6696) has a Buyback Yield % of -0.15 as of Jul. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lin BioScience and its competitors. According to the industry distribution chart, Lin BioScience ranks #147 out of 735 companies in the Biotechnology industry, placing it in the top 20%.
Is Lin BioScience's Buyback Yield % too high?
Lin BioScience's current Buyback Yield % is -0.15. Based on the distribution chart, Lin BioScience ranks #147 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lin BioScience has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Lin BioScience's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lin BioScience ranks #147 out of 735 companies for Buyback Yield %. This places Lin BioScience in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lin BioScience and its competitors. Lin BioScience's current Buyback Yield % is -0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lin BioScience stock overvalued right now?
Lin BioScience (ROCO:6696) has a current Buyback Yield % of -0.15. The current Buyback Yield % is -0.15. Lin BioScience's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Lin BioScience (ROCO:6696), the current Buyback Yield % is -0.15 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.
25GF Score
Get the complete analysis for ROCO:6696
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6696 has been successfully added to your 
